Deucravacitinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Subacute Cutaneous Lupus Erythematosus (SCLE). According to GlobalData, Phase II drugs for Subacute Cutaneous Lupus Erythematosus (SCLE) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Deucravacitinib LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Deucravacitinib overview

Deucravacitinib (Sotyktu) is a deuterium first-in-class molecule, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor. It is formulated as film-coated tablets, tablets for the oral route of administration. Sotyktu is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

BMS-986165 is under development for the treatment of systemic lupus erythematosus, subacute cutaneous lupus erythematosus, psoriatic arthritis, alopecia areata, ulcerative colitis and moderate to severe plaque psoriasis, pustular psoriasis, erythrodermic psoriasis, autoimmune disorders, pyoderma gangrenosum, vulvar lichen planus, lichen planopilaris, Sjögren's Syndrome, hidradenitis suppurativa and discoid lupus erythematosus. The drug candidate is administered orally as a solution. The drug candidate targets tyrosine kinase 2 (TYK2).

It was under development for the treatment of lupus nephritis and severe crohn's disease.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.

For a complete picture of Deucravacitinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.